United Therapeutics Corp (BSP:U2TH34)
R$ 137.5 (0%) Market Cap: 123.99 Bil Enterprise Value: 107.82 Bil PE Ratio: 20.20 PB Ratio: 3.91 GF Score: 65/100

United Therapeutics Corp at Leerink Global Healthcare Conference Transcript

Mar 09, 2026 / 05:00PM GMT
Release Date Price: R$134.75 (+2.83%)
Roanna Ruiz
Leerink Partners LLC - Analyst

Again for joining us at the Larin Global Healthcare Conference. My name is Rhona Ruiz. I'm one of the senior biotech analysts here at Larin, and, it is my pleasure to introduce United Therapeutics here. And on the stage I have with me Doctor Martin Rothblatt, who's really sort of led this company through a lot of different events and data and many things, milestones. So really glad to have you here.

Martine Rothblatt
United Therapeutics Corp - Chairman of the Board, Chief Executive Officer

Thank you, Rwanda. I appreciate the opportunity to be here. Yeah.

Questions & Answers

Roanna Ruiz
Leerink Partners LLC - Analyst

Great. And so I know there a lot of people know United Therapeutics, but just in case, in terms of if investors are wanting to refresh on the story a little bit, I'll ask you a big picture question before I dive into the details and just how are you thinking about the main pillars of the United Therapeutics story both commercially and in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot